Skip to main content Skip to main navigation menu Skip to site footer
logo Dermatology Reports

eISSN 2036-7406

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Archives
  • Early Access
  • Register
  • Login
  • Search
  • Contacts

Editor-in-Chief: Carlo Cota, Italy

1.0
Impact Factor 2025
1.5
CiteScore 2025
1.0
Impact Factor 2025
1.5
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • Quality of life in black African patients with keloid scars

    Komenan Kassi, Kanga Kouame, Alexandre Kouassi, Ange Allou, Isidore Kouassi, Sarah Kourouma, Elidje Ecra, Abdoulaye Sangare
    22-10-2020
    https://doi.org/10.4081/dr.2020.8312
    2056
    PDF: 889
    HTML: 32
  • Heparin-induced thrombocytopenia: a rare presentation with skin necrosis

    Filipa David, Ana Catarina Trigo, José Ribeiro, Joana Cancela
    16-10-2023
    https://doi.org/10.4081/dr.2023.9855
    836
    PDF: 491
    HTML: 22
  • Certolizumab to treat hidradenitis suppurativa

    Asem Shadid, Saud Alobaida, Yousef Binamer
    27-10-2022
    https://doi.org/10.4081/dr.2022.9566
    1972
    PDF: 751
    HTML: 42
  • 32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy Luisa Piccin1, Maria Chiara Scaini2, Valentina Salizzato1, Cristina Catoni2, Elisabetta Di Liso1, Alice Menichetti1, Chiara Cacco1|4, Chiara Gottardi1|4, Francesca Di Sarra3, Marina Coppola3, Valentina Guarneri1|4, Jacopo Pigozzo1 | 1Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS; 3Pharmacy Unit - Veneto Institute of Oncology IOV-IRCCS; 4Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

    Italian Melanoma Intergroup
    11-12-2025
    https://doi.org/10.4081/dr.2025.10774
    321
  • Adalimumab-induced facial erysipelas and its successful resolution with azithromycin in a 19-year-old female

    Caterina Mariarosaria Giorgio, Anna Balato, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Eugenia Veronica Di Brizzi
    21-02-2025
    https://doi.org/10.4081/dr.2025.10278
    488
    PDF: 322
    HTML: 20
  • Rituximab for linear immunoglobulin A bullous dermatosis

    Rummit Dhillon, Lily Park, Sarah Gabros, Tam Nguyen, Stanley Skopit
    29-12-2022
    https://doi.org/10.4081/dr.2023.9574
    1583
    PDF: 584
    HTML: 42
76 - 81 of 81 items << < 2 3 4 

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a Scientific paper
  • How to write a Review article
  • Article Processing Charge
  • Crediti ECM (Italian Authors)

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to Review
  • Thanks to Reviewers

Categories

    • XXXI Congresso Nazionale Intergruppo Melanoma Italiano (IMI)
    • IMI - Epidemiology, genetics and pathogenesis
    • IMI - Prevention and diagnosis
    • IMI - Pathological and molecular classification
    • IMI - Surgery
    • IMI - Therapy
    • Newsletter
    • Original Articles
    • Reviews
    • Case Reports

indexing

INDEXING
  • PubMed
  • PubMed Central
  • Scopus
  • DOAJ
  • ESCI
  • Google Scholar
  • OpenAlex
  • Web of Science
  • Analytics

dermatopathology

Dermatopathology

Dermatology Reports

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

 

https://godisnjak.pf.unibl.org/

https://revistascientificas.us.es/

pISSN: 2036-7392
eISSN: 2036-7406

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.